![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
BD Anderson, BL Hoesterey, DC Baker and RE Galinsky
Department of Pharmaceutics, College of Pharmacy, University of Utah, Salt Lake City.
The pharmacokinetics of 2',3'-dideoxyinosine (ddl) and its distribution to plasma, brain tissue and cerebrospinal fluid (CSF) were determined during and after 2-hr i.v. infusions of ddl (125 mg/kg/hr) in rats to define its specific pharmacokinetic parameters for subsequent studies of prodrugs designed to target this compound to the brain. Steady-state plasma concentrations of 50 micrograms/ml were obtained within 30 min after the start of infusions corresponding to a total clearance of 2.4 l/kg/hr. Postinfusion, ddl concentrations declined biphasically from plasma with alpha T1/2 = 3 min and beta T1/2 = 35 min. STeady-state concentrations of ddl in brain tissue and CSF were 2.6 micrograms/g in tissue and 0.81 microgram/ml in CSF, respectively. These values represent 4.7 and 1.5%, respectively, of the simultaneously determined plasma concentration. The estimated brain vascular space contribution to the observed brain uptake was 4.1%, obtained by least squares fitting of a compartmental pharmacokinetic model to the uptake data. Postinfusion, the elimination of ddl from the brain and CSF was significantly slower than from plasma, resulting in increased brain/plasma and CSF/plasma ratios after the infusions. The low steady- state brain/plasma or CSF/plasma ratios suggest rapid disappearance of ddl from the CNS relative to its rate of entry. These data indicate that ddl penetrates poorly into the brain. Thus, prodrugs with enhanced blood-brain barrier transport may improve the delivery of ddl to the brain.
This article has been cited by other articles:
|
|
 |
|
  J. Savolainen, J. E. Edwards, M. E. Morgan, P. J. McNamara, and B. D. Anderson Effects of a P-Glycoprotein Inhibitor on Brain and Plasma Concentrations of Anti-Human Immunodeficiency Virus Drugs Administered in Combination in Rats Drug Metab. Dispos., May 1, 2002; 30(5): 479 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Li, R. J. Boado, and W. M. Pardridge Differential Kinetics of Transport of 2',3'-Dideoxyinosine and Adenosine via Concentrative Na+ Nucleoside Transporter CNT2 Cloned from Rat Blood-Brain Barrier J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 735 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Takasawa, T. Terasaki, H. Suzuki, T. Ooie, and Y. Sugiyama Distributed Model Analysis of 3'-Azido-3'-Deoxythymidine and 2',3'-Dideoxyinosine Distribution in Brain Tissue and Cerebrospinal Fluid J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1509 - 1517. [Abstract] [Full Text]
|
|
|
|
|
|
K. Takasawa, T. Terasaki, H. Suzuki, and Y. Sugiyama In Vivo Evidence for Carrier-Mediated Efflux Transport of 3'-Azido-3'-Deoxythymidine and 2',3'-Dideoxyinosine Across the Blood-Brain Barrier via a Probenecid-Sensitive Transport System J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 369 - 375. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
